Progress and Priorities in Systemic Sclerosis: The Next 10 Years – Report from the World Scleroderma Foundation

1 David Geffen School of Medicine at UCLA, Los Angeles, California USA 2 University of Western Ontario, St. Joseph Health Care, London, Ontario Canada 3 Scleroderma Research Consultants, Litchfield, Connecticut USA 4 Division of Rheumatology, University of Pisa, Pisa Italy 5 Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London UK 6 University Hospital Zurich, Zurich Switzerland 7 Division of Rheumatology and Immunology, University of Toledo, Toledo, Ohio USA 8 Federation of European Scleroderma Associations, Dublin Ireland 9 University of Michigan Scleroderma Program, Ann Arbor, Michigan USA 10 Division of Rheumatology, Boston University School of Medicine, Boston, Massachusetts USA 11 University Department of Rheumatology, Basel Switzerland 12 Department of Experimental and Clinical Medicine/Division of Rheumatology, University of Florence, Florence Italy

[1]  B. Griffiths,et al.  Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. , 2014, JAMA.

[2]  B. Griffiths,et al.  Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis , 2014 .

[3]  M. Humbert,et al.  Targeted therapies in pulmonary arterial hypertension. , 2014, Pharmacology & therapeutics.

[4]  J. Laar,et al.  Update on Stem Cell Transplantation for Systemic Sclerosis: Recent Trial Results , 2013, Current Rheumatology Reports.

[5]  M. Mayes,et al.  Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. , 2012, Arthritis and rheumatism.

[6]  R. Steele,et al.  New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). , 2012, Clinical and experimental rheumatology.

[7]  M. Mayes,et al.  Bosentan treatment of digital ulcers related to systemic sclerosis : results from the RAPIDS-2 randomised , double-blind , placebo-controlled trial , 2010 .

[8]  R. Elashoff,et al.  Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. , 2010, Clinical and experimental rheumatology.

[9]  R. Landewé,et al.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.

[10]  D. Furst,et al.  Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. , 2015, Rheumatology.

[11]  K. Lewis.  Cyclophosphamide versus Placebo in Scleroderma Lung Disease , 2008 .

[12]  B. Thiers.  Cyclophosphamide versus Placebo in Scleroderma Lung Disease , 2007 .